In a report released today, Travis Steed from Bank of America Securities reiterated a Buy rating on Beta Bionics, Inc. (BBNX – Research Report), with a price target of $25.00.
Travis Steed has given his Buy rating due to a combination of factors that suggest Beta Bionics, Inc. is undervalued and poised for growth. Despite a recent 22% drop in stock price, the company’s future revenue estimates have increased by 3.5%. This indicates that the market may not fully recognize the potential upside of Beta Bionics’ business model, especially as the company continues to report quarterly results.
Moreover, the current valuation of Beta Bionics is seen as particularly attractive, trading at just 2x the 2026 revenue estimate, which is considered conservative. The company’s expansion plans, including increasing its salesforce and pharmacy mix, are expected to drive new patient starts and revenue growth. Additionally, market share scenarios suggest a potential 25-50% upside in 2025 revenue, further supporting the Buy rating as a strategic investment opportunity.
In another report released on March 26, Piper Sandler also reiterated a Buy rating on the stock with a $26.00 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BBNX in relation to earlier this year.